Skip to main content
Clinical Trials/NCT02726607
NCT02726607
Completed
Not Applicable

Adapting the HITSystem to Support Prevention of Mother-to-child HIV Transmission

University of Kansas Medical Center3 sites in 2 countries157 target enrollmentAugust 15, 2015
ConditionsHIV

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV
Sponsor
University of Kansas Medical Center
Enrollment
157
Locations
3
Primary Endpoint
Complete PMTCT retention
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to modify the HITSystem to engage and retain HIV+ pregnant women before, during and after delivery and evaluate the HITSystem impact on prevention of mother-to-child transmission (PMTCT) related behaviors and outcomes. HITSystem 2.0 intervention will support a range of PMTCT outcomes including retention in care, ART adherence, and integration of maternal and pediatric HIV services in low-resource settings.

Detailed Description

The study will be conducted in three phases: Phases 1: The researchers will conduct formative research (focus groups and interviews) with HIV+ pregnant women and PMTCT providers to customize communication strategies for text messaging and inform patient flow and optimal implementation across the various PMTCT-related services at the intervention site. Phase 2: The researchers will design and refine the HITSystem 2.0 technical components to support PMTCT outcomes guided by clinical content experts, technology analysts, and findings from Phase 1. Phase 3: The researchers will implement HITSystem 2.0 at one hospital over an 18 month period, and compare targeted PMTCT outcomes to those at a matched control hospital. The study will be conducted at two government hospitals in Kenya. HIV+ pregnant women will be enrolled in the HITSystem 2.0 at Kapsabet Hospital. HIV+ pregnant women receiving the current standard of PMTCT care at Nandi Hills Hospital will be the comparison group.

Registry
clinicaltrials.gov
Start Date
August 15, 2015
End Date
March 20, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sarah Kessler, PhD, MPH

Associate Professor

University of Kansas Medical Center

Eligibility Criteria

Inclusion Criteria

  • HIV+ pregnant women
  • Present for first PMTCT appointment at one of the study Hospitals
  • Own or have reliable access to mobile phone

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Complete PMTCT retention

Time Frame: first PMTCT visit during pregnancy to the return of the infant's first HIV DNA PCR test result by 12 weeks postnatal

The primary outcome is retention (complete or incomplete), measured from first PMTCT appointment until HIV status determination of the HIV-exposed infant at 12 weeks postnatal. This aggregate outcome includes completion of several intermediate outcomes throughout the PMTCT cascade of care, including: ART initiation (if not already on ART at time of pregnancy) (Yes/No), attendance at PMTCT appointments (Yes/No), a hospital delivery (Yes/No), infant enrollment in EID prior to hospital discharge (Yes/No), infant blood sample collected and HIV DNA PCR test result obtained (Yes/No). Complete retention requires completion of all of these steps.

Secondary Outcomes

  • Duration of PMTCT Retention(Date of first PMTCT appointment through date of last PMTCT service. Final eligible service is date of infant HIV PCR test.)
  • Infant HIV status(Results obtained by 12 weeks postnatal)
  • Number of antenatal PMTCT appointments attended(First antenatal PMTCT appointment through delivery date)

Study Sites (3)

Loading locations...

Similar Trials